Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report

Abstract Background Novel immunotherapies, or checkpoint inhibitors, targeting programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have significantly improved outcomes for patients with numerous different cancer types. However, owing to their exclusion fro...

Full description

Bibliographic Details
Main Authors: Marc Uemura, Van A. Trinh, Cara Haymaker, Natalie Jackson, Dae Won Kim, James P. Allison, Padmanee Sharma, Luis Vence, Chantale Bernatchez, Patrick Hwu, Adi Diab
Format: Article
Language:English
Published: BMC 2016-09-01
Series:Journal of Hematology & Oncology
Subjects:
Checkpoint inhibitors
PD-1
CTLA-4
Pembrolizumab
Tocilizumab
Crohn’s disease
Online Access:http://link.springer.com/article/10.1186/s13045-016-0309-7

Internet

http://link.springer.com/article/10.1186/s13045-016-0309-7

Similar Items